Hansa Biopharma AB (OSTO:HNSA) Total Receivables : kr190.1 Mil (As of Sep. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Total Receivables?

Hansa Biopharma AB's Total Receivables for the quarter that ended in Sep. 2024 was kr190.1 Mil.

Hansa Biopharma AB Total Receivables Historical Data

The historical data trend for Hansa Biopharma AB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Total Receivables Chart

Hansa Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Receivables

Get a 7-Day Free Trial

3.20

3.16

11.13

43.83

78.76

Hansa Biopharma AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Receivables	Get a 7-Day Free Trial															113.02	78.76	115.54	133.40	190.14

Hansa Biopharma AB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Hansa Biopharma AB Total Receivables Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansa Biopharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

HNSBF:USA 0RC7:UK 24H:Germany

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB Headlines

No Headlines